1,029 search results for “biomarkers discovery” in the Public website
-
Mortality and HyperImage: Visual analytics techniques for biomarker discovery in massive 3D-omics datasets
Over the past decade, several novel types of spatially resolved
-
Hans Aerts
Science
-
Novel target engagement biomarkers for better drug candidates
Is is possible to better predict the validity of drug candidates?
-
Pharmacometabolomics; prediction of system-wide multi-biomarker drug response
The lack of success of new CNS drugs in clinical development is in part due to the complexity of the CNS, unexpected side effects, difficulties for drugs to penetrate the brain, but also by the lack of biomarkers.
-
Multi-Biomarker Pharmacokinetic-Pharmacodynamic Relationships of Central Nervous Systems Active Dopaminergic Drugs
Discovery and development of Central Nervous System (CNS) drugs is hampered by high attrition rates.
-
Circulating cells as biomarkers in cardiovascular disease : the difference between men and women
Promotor: J. Kuiper
-
Molecular mechanisms of adverse outcome and translational biomarkers
Adverse drug reactions (ADRs) remain one of the major reasons for patient mortality and (early) drug withdrawal. Currently, different in vivo and in vitro models are used to assess the toxic potential of drugs in the pre-clinical phase. Unfortunately, the predictive value of this model does not fit…
-
Immunity in atherosclerosis: novel assays, biomarkers and therapeutic approaches
Atherosclerosis is a progressive disease resulting in the formation of an arterial plaque. Despite lipid lowering, recurrent cardiovascular events remain a risk. While atherosclerosis is primarily lipid-driven, the immune system plays a critical role in the pathophysiology.
-
Activity-based protein profiling in drug discovery
In the last decades, activity-based protein profiling (ABPP) has emerged as a powerful chemical tool that may aid the ever-challenging drug discovery process.
-
Glycoproteomics assays for prostate cancer biomarker discovery
PhD defence
-
Microengineered Human Blood Vessels For Next Generation Drug Discovery
Heart failure is a major health care problem with high mortality.
-
Metabolomic fingerprint biomarkers to guide antibiotic therapy and reduce resistance development
Ontwikkeling van resistentie tegen antibiotica kan optreden als patiënten onnodig of te lang met antibiotica behandeld worden. Diagnostiek waarmee snel een bacteriële infectie vastgesteld kan worden, of de response op antibiotica bepaald kan worden, zijn daarom belangrijk om therapie te optimaliseren…
-
Master student Maddalena Centanni awarded with Arenberg-Coimbra Group Prize
Former masterstudent Bio-Pharmaceutical Sciences Maddalena Centanni will be awarded the 2020 Arenberg Coimbra Prize for Erasmus Students. Centanni spent her six month Erasmus exchange at Uppsala Universiy in Sweden where she looked for ways to improve anti-cancer drug dosing.
-
EEG theta\beta ratio as a potential biomarker for resilience to performance anxiety.
Is EEG theta\beta ratio predictive towards the negative effects of stress on cognitive performance in individuals suffering from performance anxiety? Can we improve resilience to performance anxiety by using a theta\beta ratio neurofeedback intervention?
-
Hit Discovery
The goal of hit discovery is to identify suitable chemical starting points to modulate a drug target. A hit can be, a.o., a small molecule, a protein or mRNA. Hit identification is performed via rational design, genome mining, (targeted) library screening, or in silico approaches.
-
Target Discovery
The goal of target discovery is to identify and validate proteins and biological pathways that are involved in the disease process. Modulating these target proteins and pathways with small molecules, therapeutic proteins or other biomolecules (e.g. mRNA) could deliver an effective and safe drug or v…
-
Leiden discoveries
From the Big Bang to superconductivity. Many ground-breaking discoveries have been made in Leiden University’s long history.
-
Modeling interactions to unravel biomarkers for disease progression and treatment response
The aim of this project is to explore the use of statistical interaction models to quantify cross-omics and omics-drug interactions in large-scale clinical and experimental datasets
-
Glyco(proteo)mic Workflows for Cancer Biomarker Discovery
PhD defence
-
Data-Driven Drug Discovery Network (D4N)
The Data-Driven Drug Discovery Network (D4N) is an initiative by researchers from Leiden University and collaborators to join efforts in applying and developing novel techniques from data science to drug discovery and related topics from bioinformatics.
-
Discoveries in 2023
From nanoparticles to colliding ice planets and from biological origami to new x-ray scanner techniques: this year again, our scientists have made wonderful discoveries. From the largest numbers to the smallest molecules and from the oldest galaxies up to the latest algorithms, take a look at each institute's…
-
Drug discovery pipeline
The drug discovery pipeline is used to describe the stages in drug discovery. The earliest stage concerns with the identification of potential targets and molecules ('hits') that can modulate their function, while more advanced stages are about developing these hits into viable experimental drugs and…
-
Night of Discoveries
The Night of Discoveries is an annual event in Leiden, focusing on science and culture. The Young Academy Leiden is a recurring contributor to the Night of Discoveries.
-
Computational Drug Discovery
Research in this group, headed by Gerard van Westen, focusses on computational methods integrated in different parts of the drug discovery process. More specifically, topics include innovative treatments for cancer, selectivity modeling, translational research, allosteric modulation, drug resistance…
-
Drug Discovery & Safety
In the research programme Drug Discovery & Safety, we are interested in the efficacy and safety of new drugs and novel means to decipher these aspects. Hence, we employ advanced imaging and high-throughput screening techniques next to computational approaches such as chem- and bioinformatics.
-
Modern Drug Discovery
How are new drugs developed? This question is central to the Minor Modern Drug Discovery (MDD), which covers the entire trajectory from disease to drug molecule and vice versa. The various research groups involved offer a complementary and interdisciplinary perspective by connecting the diverse subjects…
-
Quantitative pharmacological modelling for optimizing treatment of sepsis
Sepsis is a life-threatening condition caused by a dysregulated host response to infection, it is associated with significant morbidity, mortality, and with a high financial burden on global healthcare systems. Bacterial infections are the primary cause of sepsis, but the growing prevalence of antimicrobial…
-
Cancer Drug Target Discovery
We focus on a better understanding of the mechanisms of cancer drug resistance and metastasis.
-
Cancer Drug Target Discovery
In this research group, headed by Prof. Erik Danen, the aim is to unravel cellular signaling mechanisms in normal and diseased cells, with a long-standing interest in cell adhesion signaling. In complex multicellular organisms such as ourselves, a division of labor emerges where different tissues and…
-
Drug Discovery and Safety (MSc)
The master's specialisation Drug Discovery and Safety at Leiden University provides students with research-oriented education into the discovery of new drug targets and new lead molecules, particularly in the field of cancer, through a combination of advanced imaging techniques (‘systems microscopy’),…
-
Leiden Early Drug Discovery & Development
Despite recent advances in medicine, many devastating disorders like cancer and cardiovascular, neurodegenerative and infectious diseases still lack effective treatments. In order to address this challenge, we, as scientists from Leiden University, joined hands in the LED3 network. LED3, for Leiden…
-
LED3 Drug Discovery Case Studies
To get a feeling of how we operate at LED3 when it comes to Early Drug Discovery, please browse through our case studies. When you select a case study you’ll find relevant contacts.
-
Translational drug discovery and development
We cover the entire spectrum from target identification to the evaluation of the efficacy and safety of novel medicines in clinical practice.
-
Cryptic species discovery
Do understudied animals contain hidden species?
-
LED3 Lecture: Computational Drug Discovery
Lecture
-
LED3 Lecture: Covalent Drug Discovery
Lecture
-
Predicting early Alzheimer's disease stage in human
A new research line is the development of liquid biopsy fingerprints to predict early Alzheimer’s disease (AD) stage in human in readily accessible body fluids in human (in collaboration with: Dr. Geert-Jan Groeneveld, CHDR; Prof. Elga de Vries, Free University Medical Center; and others).
-
Discovery of metastasis promoting candidate drug targets
Discovery of metastasis promoting candidate drug targets
-
Discovery of antibiotics and their targets in multidrug-resistant bacteria
Global healthcare is on the verge of an antibiotic availability crisis as bacteria have evolved resistance to nearly all known antibacterials. Identifying new antibiotics that operate via novel modes-of-action is therefore of high priority.
-
Inhibitor discovery of phospholipases and N-acyltransferases
In this thesis an activity-based probe was discovered that could visualize the activity of PLAATs. With an optimized gel-based ABPP assay in hand, screening of a compound library led to the discovery of alpha-ketoamides as a hit for PLAAT3.
-
Kinetics for drug discovery – The first step towards an improved drug discovery paradigm
Supervisor: Indira Nederpelt
-
PhD candidate combinatorial drug discovery with macrocycles
Science, Leiden Academic Centre for Drug Research (LACDR)
-
LED3 Lecture: Data Science in Drug Discovery
Lecture
-
LED3 Lecture: Chemical Biology for Drug Discovery
Lecture
-
LED3 Lecture: Proteomics in Drug Discovery
Lecture
-
LED3 Lecture: Synthetic Biology for Drug Discovery
Lecture
-
Discovery of selective diacylglycerol lipase β inhibitors
Diacylglycerol lipases (DAGLα and DAGLβ) are responsible for the biosynthesis of the endocannabinoid 2-arachidonoylglycerol (2-AG) in the brain and peripheral tissues. Selective DAGLβ inhibitors have been proposed as a potential treatment for inflammatory diseases with reduced potential for central…
-
Discovery of Reversible Monoacylglycerol Lipase Inhibitors
Monoacylglycerol lipase (MAGL) is the principal enzyme responsible for hydrolysis of the endocannabinoid 2-arachidonoylglycerol (2-AG). MAGL inhibition provides several potential therapeutic opportunities, including anti-nociceptive, anti-inflammatory and anti-cancer activity.
-
Medical Biochemistry
Medical Biochemistry is a section of the Leiden Institute of Chemistry at Leiden University. The section is headed by Prof. Dr. Hans Aerts.
-
Quan/Qual analysis of drugs and metabolites in biological matrices
Can we develop a generic method for Quan/Qual analysis of small molecule drugs, their metabolites and endogenous metabolites in (pre-)clinical samples?